keyword
MENU ▼
Read by QxMD icon Read
search

Bendamustine conditioning

keyword
https://www.readbyqxmd.com/read/27891267/marginal-zone-lymphoma-complicated-by-protein-losing-enteropathy
#1
Nadine Stanek, Peter Bauerfeind, Guido Herzog, Henriette Heinrich, Matthias Sauter, Daniela Lenggenhager, Cäcilia Reiner, Markus G Manz, Jeroen S Goede, Benjamin Misselwitz
Protein losing enteropathy (PLE) refers to excessive intestinal protein loss, resulting in hypoalbuminemia. Underlying pathologies include conditions leading to either reduced intestinal barrier or lymphatic congestion. We describe the case of a patient with long-lasting diffuse abdominal problems and PLE. Repetitive endoscopies were normal with only minimal lymphangiectasia in biopsies. Further evaluations revealed an indolent marginal zone lymphoma with minor bone marrow infiltration. Monotherapy with rituximab decreased bone marrow infiltration of the lymphoma but did not relieve PLE...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/27780577/bendamustine-induced-nephrogenic-diabetes-insipidus-in%C3%A2-a%C3%A2-patient-with-al-amyloidosis
#2
Nsabimana A Uwumugambi, Vaishali Sanchorawala, Anthony C Shelton, Lauren Stern, Craig E Gordon
Nephrogenic diabetes insipidus is a condition characterized by polyuria with dilute urine due to the inability of the principal cells of the renal collecting ducts to respond to antidiuretic hormone and concentrate urine. Nephrogenic diabetes insipidus can be drug induced, and several chemotherapeutic agents have been reported to cause it. Bendamustine is a traditional chemotherapeutic agent being studied for treatment for relapsed systemic AL amyloidosis. We report a case of a 59-year-old man with AL amyloidosis who developed partial nephrogenic diabetes insipidus after receiving bendamustine for treatment of AL amyloidosis...
October 22, 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/27739312/-treatment-of-relapsed-and-refractory-hodgkin-lymphoma-recommendations-of-the-czech-hodgkin-lymphoma-study-group
#3
H Móciková, J Marková, Ľ Gahérová, Z Král, A Sýkorová, D Belada, V Procházka, L Martinková, T Papajík, T Kozák
High-dose chemotherapy with autologous stem cell transplantation remains the current standard of treatment for young patients with Hodgkin lymphoma in first relapse or in those who are refractory to first-line treatment. The most important prognostic factors in relapses are clinical stage IV, poor performance status, bulky mass, and less than partial remission after salvage chemotherapy. Standard salvage chemotherapy in relapse before autologous transplantation has not been defined; however, DHAP and ICE are most frequently used in this setting...
2016: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/27651408/immune-pancytopenia-after-chemotherapy-in-a-patient-with-diffuse-large-b-cell-lymphoma
#4
Kazuyo Nagashima, Hiroaki Tanaka, Yurie Nagai, Yasumasa Sugita
During treatment for malignant lymphoma, cytopenia can develop for several reasons. In the treatment of cytopenia, various possibilities should be considered because inadequate treatment causes exacerbation of cytopenia and can lead to fatal conditions, such as infection and bleeding. Herein, we describe immune pancytopenia 3 months after the last exposure to chemotherapy in a patient with diffuse large B-cell lymphoma (DLBCL). She suffered from severe pancytopenia after two courses of rituximab and bendamustine therapy for a second relapse of DLBCL...
September 20, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27595282/bendamustine-added-to-allogeneic-conditioning-improves-long-term-outcomes-in-patients-with-cll
#5
I F Khouri, D Sui, E J Jabbour, B I Samuels, F Turturro, G Alatrash, P Anderlini, S Ahmed, B Oran, S O Ciurea, D Marin, A Olson, K K Patel, U R Popat, C Ledesma, T M Kadia, A Ferrajoli, J A Burger, J L Jorgensen, L J Medeiros, R L Bassett, A M Gulbis
Bendamustine has shown a favorable safety profile when included in chemotherapy regimens for several types of lymphoma, including CLL. This study investigated the long-term effect of adding bendamustine to a conditioning regimen on survival, rate of engraftment, immune recovery and GvHD after allogeneic stem cell transplantation (alloSCT) in CLL patients. These outcomes were compared with the fludarabine, cyclophosphamide and rituximab (FCR) conditioning regimen. We reviewed the data for 89 CLL patients treated on three trials at our institution...
September 5, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27429812/a-case-of-chyloperitoneum-secondary-to-follicular-lymphoma-and-a-review-of-prognostic-implications
#6
Megan Jagosky, Brice Taylor, Stephanie Parks Taylor
Chyloperitoneum, or chylous ascites, is a rare condition characterized by milky-appearing fluid with elevated triglyceride content and the presence of chylomicrons. Malignancy, specifically lymphoma, is reported to be the predominant cause in Western countries. Previously, the prognosis for patients with chyloperitoneum due to lymphoma has been reported as poor. We present a case of chyloperitoneum and chylothorax due to follicular lymphoma with excellent response to bendamustine and Rituxan. A review of the literature indicates that patients with chyloperitoneum associated with lymphoma generally have a favorable response to contemporary treatment regimens...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/27243412/novel-regimens-prior-to-autologous-stem-cell-transplantation-for-the-management-of-adults-with-relapsed-refractory-non-hodgkin-lymphoma-and-hodgkin-lymphoma-alternatives-to-beam-conditioning
#7
Alessandro Isidori, Anna Christofides, Giuseppe Visani
High-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) is the standard treatment for relapsed or refractory non-Hodgkin and Hodgkin lymphoma. Until recently, carmustine, etoposide, cytarabine and melphalan (BEAM) was the most commonly used conditioning regimen in this setting, given its acceptable efficacy and tolerability. Despite reasonable success with BEAM, carmustine is associated with a number of acute and late toxicities. Moreover, recent supply and cost issues for this agent have created an urgent need for alternative conditioning regimens...
November 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27183765/ibrutinib-imbruvica-relapsed-chronic-lymphocytic-leukaemia-and-mantle-cell-lymphoma-uncertain-impact-on-survival
#8
REVIEW
January
codynamic interactions are also likely in view of its adverse effect profile. There is no consensus on the treatment of patients with refractory or relapsed mantle cell lymphoma, or for patients with relapsed or possibly refractory chronic lymphocytic leukaemia. Ibrutinib inhibits an enzyme involved in regulating B lymphocyte activity. It has been authorised in the European Union for these conditions. Clinical evaluation of ibrutinib in mantle cell lymphoma is based on a single non-comparative trial in 111 patients, in which the median overall survival time was 22...
April 2016: Prescrire International
https://www.readbyqxmd.com/read/27088375/a-phase-ii-single-arm-prospective-study-of-bendamustine-plus-melphalan-conditioning-for-second-autologous-stem-cell-transplantation-in-de-novo-multiple-myeloma-patients-through-a-tandem-transplant-strategy
#9
M Martino, G Tripepi, G Messina, I D Vincelli, G Console, A G Recchia, M Gentile, S Molica, F Morabito
This phase II trial evaluates, for the first time, the safety and efficacy of bendamustine plus high-dose melphalan (HDM) as a conditioning regimen before the second autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM) patients. In total, 32 ASCT patients received HDM (200 mg/m(2)) as conditioning for the first ASCT. After 3-6 months from the first ASCT, responding patients underwent a second ASCT following bendamustine (200 mg/m(2)) and HDM (140 mg/m(2)). High-dose chemotherapy and ASCT were performed with complete neutrophil and platelet recovery in all patients...
September 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27055578/therapeutic-approach-to-patients-with-chronic-lymphocytic-leukemia-and-significant-comorbid-conditions
#10
Lukáš Smolej
Clinical trials in chronic lymphocytic leukemia (CLL) have focused mainly on younger fit patients until recently. However, CLL is a disease of elderly and many patients have significant comorbid conditions which together with advanced age preclude the use of aggressive regimens like FCR (fludarabine, cyclophosphamide, rituximab). Therefore, parameters such as performance status, renal function and number/severity of comorbidities together with clinical judgment should be used to guide the decision-making process regarding intensity of treatment...
April 8, 2016: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/27055577/refractory-chronic-lymphocytic-leukemia-a-therapeutic-challenge
#11
Lukáš Smolej
Despite impressive therapeutic progress represented by the advent of chemoimmunotherapy, chronic lymphocytic leukemia (CLL) remains incurable by conventional modalities. Refractory CLL defined by non-response to treatment or relapse/progression within 6 months is associated with multiple unfavourable prognostic factors such as p53 pathway disruption, deteriorating patient condition, increased risk of severe infections, and poor response to treatment, resulting in a very short overall survival. Therefore, refractory CLL represents a highly challenging situation for the hematologist as well as the patient...
April 8, 2016: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/26890007/state-of-the-art-treatment-and-novel-agents-in-chronic-lymphocytic-leukemia
#12
Paula Cramer, Michael Hallek, Barbara Eichhorst
Chemoimmunotherapy is the established first-line treatment of patients with chronic lymphocytic leukemia (CLL) who do not display the high-risk genetic features del(17p) and/or TP53 mutation: Physically fit patients without or with only mild comorbidities should receive fludarabine, cyclophosphamide and rituximab, while bendamustine and rituximab can be considered in fit elderly patients of over 65 years and in patients with a higher risk of infections. Patients with relevant coexisting conditions should receive chlorambucil with a CD20 antibody, preferably obinutuzumab...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/26783429/a-case-of-neurolymphomatosis-caused-by-follicular-lymphoma-successfully-treated-with-bendamustine
#13
Masayuki Umeda, Tadakazu Kondo, Momoko Nishikori, Toshiyuki Kitano, Masakatsu Hishizawa, Norimitsu Kadowaki, Akifumi Takaori-Kondo
Currently, there is no standard treatment for neurolymphomatosis because of the scarcity of clinical studies. Here, we report the successful treatment of neurolymphomatosis caused by follicular lymphoma with bendamustine, which could be an effective treatment option for this condition.
January 2016: Clinical Case Reports
https://www.readbyqxmd.com/read/26524266/bendamustine-based-conditioning-for-non-hodgkin-lymphoma-autologous-transplantation-an-increasing-risk-of-renal-toxicity
#14
LETTER
S Garciaz, D Coso, J-M Schiano de Collela, F Broussais, A-M Stoppa, T Aurran, C Chabannon, A Helvig, L Xerri, D Blaise, R Bouabdallah
No abstract text is available yet for this article.
February 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/26506993/trastuzumab-associated-flagellate-erythema-report-in-a-woman-with-metastatic-breast-cancer-and-review-of-antineoplastic-therapy-induced-flagellate-dermatoses
#15
Philip R Cohen
INTRODUCTION: Flagellate erythema presents as erythematous, individual and intermingled, linear streaks in a whiplash-like pattern. Several conditions, including antineoplastic agents, have been associated with flagellate erythema. A woman with metastatic breast cancer who developed flagellate erythema after receiving trastuzumab is described and the features of flagellate erythema associated with other antineoplastic agents are reviewed. METHODS: PubMed was used to search the following terms, separately and in combination: agent, antineoplastic, bendamustine, bleomycin, breast, cancer, chemotherapy, dermatitis, dermatosis, docetaxel, erythema, flagellate, Herceptin, pigmentation, peplomycin, therapy, and trastuzumab...
October 27, 2015: Dermatology and Therapy
https://www.readbyqxmd.com/read/26489499/-therapeutic-options-for-slow%C3%A2-go-patients-with-chronic-lymphocytic-leukemia
#16
REVIEW
L Smolej
Chronic lymphocytic leukemia is a disease of older patients, most of them suffering from significant comorbidities or functional limitations (so -called 'slow- go' patients). Unfortunately, clinical trials in chronic lymphocytic leukemia have until recently focused mainly on the subgroup of younger patients in good overall condition ('go- go' patients). Clinico- biological parameters, such as performance status, calculated creatinine clearance, the number and severity of comorbidities along with individual clinical assessment can help guide decisions relating to the objectives and ultimately the intensity of treatment...
2015: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/26196503/esters-of-bendamustine-are-by-far-more-potent-cytotoxic-agents-than-the-parent-compound-against-human-sarcoma-and-carcinoma-cells
#17
Stefan Huber, Johannes Philip Huettner, Kristina Hacker, Günther Bernhardt, Jörg König, Armin Buschauer
The alkylating agent bendamustine is approved for the treatment of hematopoietic malignancies such as non-Hodgkin lymphoma, chronic lymphocytic leukemia and multiple myeloma. As preliminary data on recently disclosed bendamustine esters suggested increased cytotoxicity, we investigated representative derivatives in more detail. Especially basic esters, which are positively charged under physiological conditions, were in the crystal violet and the MTT assay up to approximately 100 times more effective than bendamustine, paralleled by a higher fraction of early apoptotic cancer cells and increased expression of p53...
2015: PloS One
https://www.readbyqxmd.com/read/26158513/targeting-neddylation-induces-dna-damage-and-checkpoint-activation-and-sensitizes-chronic-lymphocytic-leukemia-b-cells-to-alkylating-agents
#18
C Paiva, J C Godbersen, A Berger, J R Brown, A V Danilov
Microenvironment-mediated upregulation of the B-cell receptor (BCR) and nuclear factor-κB (NF-κB) signaling in CLL cells resident in the lymph node and bone marrow promotes apoptosis evasion and clonal expansion. We recently reported that MLN4924 (pevonedistat), an investigational agent that inhibits the NEDD8-activating enzyme (NAE), abrogates stromal-mediated NF-κB pathway activity and CLL cell survival. However, the NAE pathway also assists degradation of multiple other substrates. MLN4924 has been shown to induce DNA damage and cell cycle arrest, but the importance of this mechanism in primary neoplastic B cells has not been studied...
July 9, 2015: Cell Death & Disease
https://www.readbyqxmd.com/read/26085055/bendamustine-in-multiple-myeloma
#19
REVIEW
Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lucio Morabito, Francesco Mendicino, Giovanna Giagnuolo, Fortunato Morabito
The advent of high-dose melphalan with autologous stem-cell transplantation (ASCT), the availability of novel agents such as thalidomide, lenalidomide (immunomodulatory drugs or IMiDs) and bortezomib (proteasome inhibitor) and improvements in supportive care have allowed to increase overall survival in multiple myeloma (MM) patients; nevertheless, MM remains an incurable pathology. For this reason, newer agents are required for continued disease control. Bendamustine is an old drug rediscovered in the last decade...
November 2015: European Journal of Haematology
https://www.readbyqxmd.com/read/26052090/determination-and-characterization-of-two-degradant-impurities-in-bendamustine-hydrochloride-drug-product
#20
Wenhua Chen, Limin Zou, Fei Zhang, Xiangyang Xu, Liandi Zhang, Mingyi Liao, Xiaoqiang Li, Li Ding
Bendamustine hydrochloride is an alkylating antitumor agent with a good efficacy in the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (B-NHL). Under the stressed conditions, two degradant impurities in bendamustine hydrochloride drug product were detected by high-performance liquid chromatography. These two degradant impurities were isolated from preparative liquid chromatography, and were further characterized using Q-TOF/MS and nuclear magnetic resonance (NMR). Based on the MS and NMR spectral data, they were characterized as 4-[5-(2-chloro-ethylamino)-1-methyl-1H-benzoimidazol-2-yl] butyric acid hydrochloride (impurity-A) and 4-{5-[[2-(4-{5-[bis-(2-chloroethyl) amino]-1-methyl-1H-benzoimidazol-2-yl}-butyryloxy)-ethyl]-(2-chloroethyl)amino]-1-methyl-3a, 7a-dihydro-1H-benzoimidazol-2-yl} butyric acid hydrochloride (impurity-B)...
November 2015: Journal of Chromatographic Science
keyword
keyword
89535
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"